

---

Type the name of the educational activity above this line.

---

Type your name above this line.

---

Type the activity's date(s) above.

As a provider of accredited continuing education (CE) for health professionals, AffinityCE is committed to providing balance, independence, objectivity, and scientific rigor in all its educational activities.

All individuals in a position to control the content of a CE activity (including faculty, planners, reviewers, or others) are required to disclose all financial relationships with ineligible companies (commercial interests) for a period of **twenty-four (24) months** prior to the start of the educational activity.

**Ineligible companies** are defined by the ACCME as “those [entities] whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” **Financial interests** can include such things as grants or research support; or being an employee, consultant, holder of stock in a privately-held company, etc. See page 3 for more detailed definitions.

**If you have no financial interests with ineligible companies to disclose:**

Complete this page, attest (sign) electronically, and return the document to [ce@affinityced.com](mailto:ce@affinityced.com).

I **do not have** any financial interests with ineligible companies to disclose.

**Unlabeled and unapproved uses:** Presentations that provide information, in whole or in part, related to non-FDA approved uses for drug products and/or devices must clearly acknowledge the unlabeled indications or the investigational nature of their proposed uses to the audience. Speakers must disclose their intent to discuss non-FDA approved uses for commercial products and/or devices.

I **do not** intend to reference unlabeled or unapproved uses of drugs or products.

I **intend** to discuss non-FDA uses of drug products and/or devices and their unlabeled indications. I will disclose to the audience when this discussion takes place.

**Attestation.** Fill in the fields below to attest that the information you are providing on this disclosure form is true and accurate. Return to [ce@affinityced.com](mailto:ce@affinityced.com).

---

Type your name above this line.

---

Type today's date above this line.

**If you have relevant financial interests with ineligible companies to disclose:**

Complete the following page, attest (sign) electronically, and return it to [ce@affinityced.com](mailto:ce@affinityced.com).

Complete the fields in the table below for each financial interest with an ineligible company. See page 3 for detailed definitions and room for more relationships to disclose.

Name of company with which you have a financial relationship (e.g., XYZ Pharmaceutical, Inc.)	Nature of the financial relationship(s) (e.g., Advisory Board Member)	Check box if the relationship ended within the past 24 months

**i** The information provided above **will be disclosed to learners** before the start of the activity.

**Unlabeled and unapproved uses:** Presentations that provide information, in whole or in part, related to non-FDA approved uses for drug products and/or devices must clearly acknowledge the unlabeled indications or the investigational nature of their proposed uses to the audience. Speakers must disclose their intent to discuss non-FDA approved uses for commercial products and/or devices.

I **do not** intend to reference unlabeled or unapproved uses of drugs or products.

I **intend** to discuss non-FDA uses of drug products and/or devices and their unlabeled indications. I will disclose to the audience when this discussion takes place.

**Only for faculty or authors** who are executives, employees, or owners of companies whose products are related to healthcare and patient treatments, please complete this section.

---

Type your title and role at the company in the space above this line.

Select an answer (“Yes” or “No”) if the content of your presentation...	Yes	No
Will contain any references to the business lines or products of your employer or company		
Will be limited to basic science research, such as pre-clinical and drug discovery, or the methodologies of research, and not make care recommendations		

**Attestation.** Fill in the fields below to attest that the information you are providing on this disclosure form is true and accurate. Return to [ce@affinityced.com](mailto:ce@affinityced.com).

---

Type your name above this line.

---

Type today’s date above this line.

If necessary, enter additional disclosures into the table below.

Name of company with which you have a financial relationship (e.g., XYZ Pharmaceutical, Inc.)	Nature of the financial relationship(s) (e.g., Advisory Board Member)	Check box if the relationship ended within the past 24 months

**More detailed definitions of entity and relationship terms from ACCME**

- Ineligible company.** Any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Entities for which you must disclose your financial relationships are: ① biomedical startups that have begun a governmental regulatory approval process; ② compounding pharmacies that manufacture proprietary compounds; ③ device manufacturers or distributors; ④ diagnostic labs that sell proprietary products; ⑤ growers, distributors, manufacturers, or sellers of medical foods and dietary supplements; ⑥ manufacturers of health-related wearable products; ⑦ pharmaceutical companies or distributors; and ⑧ reagent manufacturers or sellers.  
See [accme.org/standards](http://accme.org/standards) for the latest information from the ACCME.
- Financial relationships.** Examples include: ① being an employee, having an executive role, or being an owner (of a pharmaceutical or medical device manufacturer); ② researcher; ③ consultant; ④ advisor; ⑤ speaker; ⑥ independent contractor (including contracted research); and ⑦ royalties or patent beneficiary. Individual stocks and stock options of privately-held companies should be disclosed; but diversified mutual funds do not need to be disclosed. Research funding from companies should be disclosed by the principal or named investigator even if that individual’s institution receives the research grant and manages the funds.